Company Overview and News
EDMONTON, Alberta, May 08, 2018 (GLOBE NEWSWIRE) -- Melcor Developments Ltd. (TSX:MRD), an Alberta-based real estate development and asset management company, today reported results for the quarter ended March 31, 2018. Revenue for the quarter was $44.41 million, up 15% over Q1-2017. Revenue growth was driven by an increase in sales in the Community Development division which led to a 54% increase in divisional revenue coupled with stable results in our income-producing divisions.
Oslo, 24 April 2018 - Entra appoints new head of digital and business development and strengthens core operations with new leadership for property management and project development.
When Canberra property developer Matt James needs an escape from work and travelling, he looks no further than his Kingston foreshore apartment.
QTS Realty Trust, Inc. (NYSE:QTS) Q4 2017 Earnings Conference Call February 21, 2018 8:30 AM ET
(PRESS RELEASE) – Capital Trust Residencies (Pvt) Ltd clinched the prestigious awards for the Best Condominium Development (Sri Lanka), Best Condominium Development in Colombo and Best Residential Interior Design (Sri Lanka)at the Asia Property Awards 2017 held in Singapore, recently.
EDMONTON, AB--(Marketwired - November 03, 2017) - Melcor Developments Ltd. (TSX: MRD), an Alberta-based real estate development and asset management company, today reported results for the quarter ended September 30, 2017. Third quarter revenue was $62.80 million, down 1% over Q3-2016. Revenue for the first half of the year was $148.32 million, up 9%.
· Underlying cost to income ratio¹ improved to 44% (H1 2016: 46%) while continuing to invest in the Group
EDMONTON, AB--(Marketwired - August 09, 2017) - Melcor Developments Ltd. (TSX: MRD), an Alberta-based real estate development and asset management company, today reported results for the quarter ended June 30, 2017. Revenue was $46.96 million in the quarter, up 12% over Q2-2016. Revenue for the first half of the year was $85.52 million, up 18%.
Good day, ladies and gentlemen, and welcome to the General Growth Properties (sic) [GGP] (00:03) Second Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this call is being recorded.
MANILA, Philippines - Port operators such as International Container Terminal Services Inc. of tycoon Enrique Razon, Romero- owned RII Builders and Tanco-led Asian Terminals Inc. will have the chance to expand in Russia following the initiatives of the business delegation in the Eurasian country last month.
The Group is pleased to announce its interim results for the six months ended 28 February 2017. Formation Group is focused solely on property development and project management providing professional services to its clients within this sector.
THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO, CANADA, JAPAN, AUSTRALIA, THE REPUBLIC OF SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
Excellent project structuring skills and the growth in the investment property portfolio have de-risked First Sponsor's property development business.
KUALA LUMPUR, Malaysia, April 14, 2017 /PRNewswire/ -- Mah Sing Group Berhad (Mah Sing) celebrated another achievement as it clinched the 2017 Frost & Sullivan Property Development Company of the Year at an award banquet held at the Hilton KL yesterday.
Gamuda is a leading infrastructure developer in Malaysia. It also engages in property development activities and operates infrastructure concessions.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...